An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced new preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), to be presented at the EAACI 2022 Hybrid Congress from July 1-3 in Prague. Pradeep Bista, VP of Discovery and Translational Sciences, will present findings on July 3 at 11:15 am CEST. STAR-0215 is designed for long-acting attack prevention, with dosing every three months or longer. The company plans to file an Investigational New Drug Application mid-year and initiate a Phase 1a trial with results expected by year-end.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in two presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2022 Hybrid Congress which takes place from July 1-3, 2022 in Prague, Czech Republic.
Pradeep Bista, Ph.D., Vice President, Discovery and Translational Sciences at Astria Therapeutics, will present “STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrates Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys” during a Flash Talks session on Sunday, July 3, at 11:15 am CEST. A poster version of this presentation, e-poster #100242 will also be available to delegates on the EAACI digital platform during and after the event.
A second presentation, e-poster #001263 titled “STAR-0215 is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE” will also be available on the EAACI digital platform to delegates.
STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every 3 months or longer. The company’s goal is to provide the most patient-friendly preventative treatment option for people living with HAE. Astria expects to file an Investigational New Drug Application for STAR-0215 mid-year this year and plans to initiate a Phase 1a trial shortly thereafter with initial results anticipated by year-end.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the expected timing for filing an IND for STAR-0215; the expected commencement of a Phase 1a clinical trial for STAR-0215 the potential attributes and differentiated profile of STAR-0215 as a treatment for HAE; and the Company’s broader goal to meet the unmet needs of patients with rare and niche allergic and immunological diseases. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Company’s product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties: related to changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including the COVID-19 pandemic; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of pre-clinical studies may not be replicated in clinical studies, the Company’s ability to enroll patients in our clinical trials, and the risk that any of the Company’s clinical trials may not commence, continue or be completed on time, or at all; decisions made by, or feedback received from, the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and other review bodies with respect to STAR-0215 and any future product candidates; the Company’s ability to manufacture sufficient quantities of drug substance and drug product on a cost-effective and timely basis; the Company’s ability to obtain, maintain and enforce intellectual property rights for STAR-0215 and any other future product candidates; competition with respect to STAR-0215 in HAE or with respect to any other future product candidates; the anticipated position and attributes of STAR-0215 in HAE based on its pre-clinical profile, pharmacokinetic modeling and other data; the Company’s ability to manage its cash usage and the possibility of unexpected cash expenditures; the Company’s ability to obtain necessary financing to conduct its planned activities and to manage unplanned cash requirements; general economic and market conditions; as well as the risks and uncertainties set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. The Company may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on the Company’s forward-looking statements. Neither the Company, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
What is the significance of STAR-0215 presented by Astria Therapeutics at EAACI 2022?
STAR-0215 is a monoclonal antibody for hereditary angioedema, offering long-acting prevention with dosing every three months. Its presentation highlights new preclinical data.
When will Astria Therapeutics present STAR-0215 at the EAACI 2022 Hybrid Congress?
Astria Therapeutics will present STAR-0215 on July 3, 2022, at 11:15 am CEST during a Flash Talks session.
What are the expectations for STAR-0215 post-EAACI 2022?
Astria Therapeutics aims to file an Investigational New Drug Application for STAR-0215 mid-year and initiate a Phase 1a trial shortly thereafter, with initial results anticipated by year-end.
What type of drug is STAR-0215 and what condition does it target?
STAR-0215 is a long-acting monoclonal antibody plasma kallikrein inhibitor aimed at treating hereditary angioedema.
Where is the EAACI 2022 Hybrid Congress being held?
The EAACI 2022 Hybrid Congress is taking place in Prague, Czech Republic from July 1-3, 2022.
